- Home
- GPN vs RPRX Comparison
GPN vs RPRX Comparison
Compare GPN & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GPN | RPRX |
|---|---|---|
| Founded | 1967 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1B | 25.9B |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GPN | RPRX |
|---|---|---|
| Price | $88.39 | $58.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 5 |
| Target Price | ★ $92.56 | $51.40 |
| AVG Volume (30 Days) | 2.1M | ★ 2.9M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | 1.41% | ★ 1.90% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.71 |
| Revenue | ★ $3,975,163,000.00 | $2,378,193,000.00 |
| Revenue This Year | $63.81 | $38.63 |
| Revenue Next Year | $6.27 | $4.73 |
| P/E Ratio | ★ N/A | $82.35 |
| Revenue Growth | ★ 17.92 | 5.06 |
| 52 Week Low | $61.16 | $34.63 |
| 52 Week High | $95.88 | $64.38 |
Technical Indicators
Market Signals| Indicator | GPN | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.28 | 41.75 |
| Support Level | $66.88 | $55.66 |
| Resistance Level | $90.85 | $59.64 |
| Average True Range (ATR) | 2.40 | 1.37 |
| MACD | -0.79 | -0.57 |
| Stochastic Oscillator | 31.13 | 10.86 |
Price Performance
Historical ComparisonAbout GPN Global Payments Inc.
Global Payments is a leading provider of payment processing and software solutions and historically focused on serving small and midsize merchants. The Worldpay acquisition pushes the company into the large merchant space and expands the company's international operations. Following the Worldpay acquisition, the company will process about $4 trilliion in payment volume.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.